SCHEMBL458603

SCHEMBL458603

CC(C)(C)C(=O)Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 9/20 1.00
PTPN13 Q12923 3/20 1.00
CTSL P07711 2/20 1.00
PTPN1 P18031 2/20 1.00
CTSS P25774 2/20 1.00
LCK P06239 1/20 1.00
PTPN2 P17706 1/20 1.00
MAPT P10636 4/20 0.62
NPC1 O15118 3/20 0.62
ALDH1A1 P00352 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAOA P21397 1/20 0.62
CYP1A2 P05177 1/20 0.57
POLB P06746 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29361459 1.00 PTPRC (1.00) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL30087501 1.00 PTPRC (1.00) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL22321739 0.97 PTPRC (0.94) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL29538970 0.97 PTPRC (0.94) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL8610211 0.95 PTPRC (0.91) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL25797323 0.87 PTPRC (0.76) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL22336186 0.86 PTPRC (0.76) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL22336242 0.86 PTPRC (0.76) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL22008429 0.86 PTPRC (0.75) PTPRCPTPN13CTSLPTPN1CTSS
SCHEMBL20572260 0.86 PTPRC (0.75) PTPRCPTPN13CTSLPTPN1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3384007-B1 IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) 2024-03-27 EP claimed
EP-3019596-B1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS HONG GUAN LTD (CN) 2023-07-05 EP claimed
WO-2023285654-A2 COMPOUNDS FOR THE TREATMENT OF COVID-19 DOMPE' FARMACEUTICI SPA (IT) 2023-01-19 WO claimed
EP-4119145-A1 COMPOUNDS FOR THE TREATMENT OF COVID-19 Dompe' Farmaceutici S.P.A. (IT) 2023-01-18 EP claimed
WO-2022181515-A1 COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR 国立大学法人京都大学 2022-09-01 WO claimed
WO-2017004167-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2017-01-05 WO claimed
US-9492408-B2 Protection from chemical-induced acute lung injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2016-11-15 US claimed
US-20160145581-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS HONG GUAN, LTD. (CN) 2016-05-26 US claimed
US-20150119468-A1 PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY University of Pittsburgh–of the Commonwealth System of Higher Education (US) 2015-04-30 US claimed
US-8778620-B2 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2014-07-15 US claimed
US-20130130279-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2013-05-23 US claimed
US-20120309029-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2012-12-06 US claimed
US-8227202-B2 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2012-07-24 US claimed
EP-2304436-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT Nodality, Inc. (US) 2011-04-06 EP claimed
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CHILDREN'S MEDICAL CENTER CORPORATION 2011-01-06 US claimed
EP-2179037-A2 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT Nodality, Inc. (US) 2010-04-28 EP claimed
WO-2010006291-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT NODALITY, INC. (US) 2010-01-14 WO claimed
US-20100009364-A1 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2010-01-14 US claimed
US-20090098594-A1 Methods for diagnosis prognosis and methods of treatment NODALITY, INC. (US) 2009-04-16 US claimed
WO-2009025847-A2 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2009-02-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CSF3R, CSF1R, ATM PTPRC 42/4885PTPN13 37/4885CTSL 1076/4885
US-20160145581-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS AHCY, GSKIP, AHCYL1 PTPRC 2167/4885PTPN13 1716/4885CTSL 3735/4885
US-20150119468-A1 PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY DUSP10, CASP10, PHF20 PTPRC 139/4885PTPN13 66/4885CTSL 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.